Akorn Pays Out $7.9m In Medicare Fraudulent Billing Case
The Whistleblower Behind The Case Will Receive $946,000 From The Settlement
Executive Summary
Akorn has agreed to pay out $7.9m to settle allegations that it deliberately sold three generic drugs as prescription-only when they should have been classed as over-the-counter, in a deal with the US Department of Justice. The mislabeling led Medicare Part D to pay out for the drugs for around a year despite the products not being eligible for Medicare coverage.